Work

Safety and Efficacy of 20 Cycles of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Year: 2025

Type: article

Abstract: Current randomized controlled data ([1][1] , [2][2]) demonstrate the safety and efficacy of 6 cycles of [177Lu]Lu-PSMA-617 therapy in men with metastatic castration-resistant prostate cancer. In our first phase 2 trial ([3][3]), 15 of 30 patients received additional cycles; 11 (73%) had a subsequent

Source: Journal of Nuclear Medicine

DOI: 10.2967/jnumed.124.269447

Authors: Kerry E. Jewell, James P. Buteau, Elizabeth Medhurst, Edmond M. Kwan, Shahneen Sandhu, Arun A. Azad, Michael S. Hofman

Institutions: The University of Melbourne, Peter MacCallum Cancer Centre, Monash University

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Prostate Cancer Foundation, Prostate Cancer Foundation of Australia, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, National Health and Medical Research Council

OpenAlex ID: W4408404228

FWCI: 2.179

Cites: 6

Cited by: 4

Related to: 10